Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

The drug has been in the news recently because of incidents of dysgeusia — a bad ... may see a recurrence of symptoms after a brief recovery. In addition, researchers have found in some cases ...

Dysgeusia is an uncommonly reported side effect associated with angiotensin-converting enzyme inhibitors (ACE inhibitors). [1] The onset is almost always within the first 3 months and is ...

Amgen today announced that the global Phase 3 DeLLphi-304 clinical trial evaluating IMDELLTRA® (tarlatamab-dlle) as a treatment for patients with small cell lung cancer (SCLC) who progressed on or ...